Skip to main content

Table 2 Demographic and clinical characteristics of the Pharmachild patients with infections

From: Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

Data aren(%) or medians with IQR range

Patients adjudicated* (N = 572)

Patients not adjudicated* (N = 323)

Patients with infections (N = 895)

P(patients adjudicated vs not adjudicated)

 

Females

388 (67.8%)

241 (74.6%)

629 (70.3%)

0.033

 

Age at onset

3.1 (1.7–6.7)

4.1 (2.1–8.5)

3.5 (1.9–7.3)

0.001

 

Age at JIA diagnosis

3.7 (2.1–7.5)

4.9 (2.4–9.5)

4.1 (2.2–8.1)

0.001

 

Disease duration at last FU

7.6 (5.0–11.1)

5.8 (3.1–10.3)

7.1 (4.2–10.8)

< 0.001

 

JIA category

   

0.004

 

Systemic

120 (20.9%)

37 (11.4%)

157 (17.5%)

  

Oligo persistent

101 (17.7%)

80 (24.8%)

181 (20.2%)

  

Oligo extended

100 (17.5%)

50 (15.5%)

150 (16.8%)

  

Polyarticular RF-

132 (23.1%)

84 (26.0%)

216 (24.1%)

  

Polyarticular RF+

19 (3.3%)

15 (4.6%)

34 (3.8%)

  

Psoriatic

25 (4.4%)

8 (2.5%)

33 (3.7%)

  

Enthesitis

36 (6.3%)

21 (6.5%)

57 (6.4%)

  

Undifferentiated

39 (6.8%)

28 (8.7%)

67 (7.5%)

  

Systemic glucocorticoids

336 (58.7%)

154 (47.7%)

490 (54.7)

0.001

 

Synthetic DMARDs

Methotrexate

532 (93.0%)

289 (89.5%)

821 (91.7%)

0.065

< 0.001

 

Cyclosporine

90 (15.7%)

13 (4.1%)

103 (11.5%)

< 0.001

 

Sulfasalazine

66 (11.5%)

28 (8.7%)

94 (10.5%)

0.179

 

Leflunomide

40 (7.0%)

28 (8.7%)

68 (7.6%)

0.364

 

Azathioprine

17 (3.0%)

6 (1.9%)

23 (2.6%)

0.312

 

Hydroxychloroquine

14 (2.4%)

9 (2.8%)

23 (2.6%)

0.758

 

Thalidomide

7 (1.2%)

2 (0.6%)

9 (1.0%)

0.501

 

Biologic DMARDs

Etanercept

298 (52.1%)

126 (39.0%)

424 (47.4%)

< 0.001

 

Adalimumab

178 (31.1%)

82 (25.4%)

260 (29.1%)

0.070

 

Tocilizumab

103 (18.0%)

19 (5.9%)

122 (13.6%)

< 0.001

 

Infliximab

84 (14.7%)

17 (5.3%)

101 (11.3%)

< 0.001

 

Anakinra

54 (9.4%)

28 (8.7%)

82 (9.2%)

0.701

 

Abatacept

39 (6.8%)

17 (5.3%)

56 (6.3%)

0.356

 

Canakinumab

28 (4.9%)

10 (3.1%)

38 (4.2%)

0.200

 

Rituximab

26 (4.5%)

3 (0.9%)

29 (3.2%)

0.003

 

Golimumab

14 (2.4%)

6 (1.9%)

20 (2.2%)

0.566

 

Certolizumab

4 (0.7%)

1 (0.3%)

5 (0.6%)

0.453

 

Other biologic agents

2 (0.3%)

1 (0.3%)

3 (0.3%)

1.000

 
  1. Data are n (%) or medians with IQR range. Drugs refer to their administration at any time during the patient’s history and are sorted by their descending frequencies. *The adjudicated patients are represented by those with opportunistic infections as per the provisional list of opportunistic pathogens/presentations (step 1), and very severe/severe or serious non-opportunistic infections. The remaining ones represent the not adjudicated patients. JIA juvenile idiopathic arthritis, FU follow-up, RF rheumatoid factor, DMARDs disease-modifying anti-rheumatic drugs
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us